Correlation Between Inhibrx and Inozyme Pharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Inhibrx and Inozyme Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inhibrx and Inozyme Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inhibrx and Inozyme Pharma, you can compare the effects of market volatilities on Inhibrx and Inozyme Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inhibrx with a short position of Inozyme Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inhibrx and Inozyme Pharma.

Diversification Opportunities for Inhibrx and Inozyme Pharma

0.62
  Correlation Coefficient

Poor diversification

The 3 months correlation between Inhibrx and Inozyme is 0.62. Overlapping area represents the amount of risk that can be diversified away by holding Inhibrx and Inozyme Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Inozyme Pharma and Inhibrx is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inhibrx are associated (or correlated) with Inozyme Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Inozyme Pharma has no effect on the direction of Inhibrx i.e., Inhibrx and Inozyme Pharma go up and down completely randomly.

Pair Corralation between Inhibrx and Inozyme Pharma

Given the investment horizon of 90 days Inhibrx is expected to generate 0.56 times more return on investment than Inozyme Pharma. However, Inhibrx is 1.77 times less risky than Inozyme Pharma. It trades about -0.01 of its potential returns per unit of risk. Inozyme Pharma is currently generating about -0.25 per unit of risk. If you would invest  1,514  in Inhibrx on December 29, 2024 and sell it today you would lose (82.00) from holding Inhibrx or give up 5.42% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Inhibrx  vs.  Inozyme Pharma

 Performance 
       Timeline  
Inhibrx 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Inhibrx has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong fundamental drivers, Inhibrx is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors.
Inozyme Pharma 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Inozyme Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Inhibrx and Inozyme Pharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Inhibrx and Inozyme Pharma

The main advantage of trading using opposite Inhibrx and Inozyme Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inhibrx position performs unexpectedly, Inozyme Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inozyme Pharma will offset losses from the drop in Inozyme Pharma's long position.
The idea behind Inhibrx and Inozyme Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Other Complementary Tools

Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity